文献速递眼外伤角膜与眼表疾病

美国食品药品监督管理局CustomFlex人工虹膜临床试验结果

Results of the United States Food and Drug Administration Clinical Trial of the CustomFlex Artificial Iris.
PubMed 文献 · Ophthalmology · 2022-02-05

这项多中心、前瞻性、非随机、非盲法干预试验评估了定制可折叠人工虹膜(CustomFlex Artificial Iris)治疗先天性和获得性虹膜缺损的安全性和有效性,植入时间为2013年11月26日至2017年12月1日,术后12个月随访显示日间和夜间光敏感及眩光显著降低,NEI VFQ-25总分提高15.4分,93.8%患者美容改善,未发现器械相关CDVA下降超过2行,中位内皮细胞密度丢失6个月为5.3%、12个月为7.2%。

要点

  • 术后12个月,日间和夜间重度光敏感分别降低59.7%和41.5%,日间和夜间重度眩光分别降低53.1%和48.5%(均P < 0.0001)。
  • NEI VFQ-25总分提高15.4分(P < 0.0001),93.8%患者报告美容改善。
  • 中位内皮细胞密度丢失6个月为5.3%,12个月为7.2%;未发现器械相关CDVA下降超过2行。

核心结论

  • 人工虹膜在所有关键安全性终点(器械、人工晶状体或植入手术相关不良事件)和关键有效性终点(光敏感和眩光降低、健康相关生活质量改善、美容满意度)上均达标。
  • 该器械对于治疗先天性或获得性虹膜缺损引起的症状和不可接受的外观是安全有效的。

研究设计与样本

  • 多中心、前瞻性、非盲法、非随机、干预性临床试验。
  • 纳入有畏光、敏感性继发于部分或完全先天或获得性虹膜缺损、或两者兼有的患者。
  • 2013年11月26日至2017年12月1日期间,由4种不同手术技术之一植入定制可折叠人工虹膜。
  • 术后1天、1周、1、3、6、12个月进行随访评估。

主要发现

  • 术后12个月检查发现,日间重度光敏感降低59.7%(P < 0.0001),夜间重度光敏感降低41.5%(P < 0.0001),日间重度眩光降低53.1%(P < 0.0001),夜间重度眩光降低48.5%(P < 0.0001)。
  • NEI VFQ-25总分提高15.4分(P < 0.0001)。
  • 术后12个月,93.8%的患者根据全球美容改善量表报告美容改善。
  • 未发现与器械相关的CDVA下降超过2行。
  • 中位ECD丢失在术后6个月为5.3%,术后12个月为7.2%。

关键数值与推荐

  • 主要结局指标为术后12个月的光敏感、眩光、视觉症状、NEI VFQ-25评分、全球美容改善量表评级、假体相关不良事件、IOL相关不良事件和手术相关不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate safety and efficacy of a custom-manufactured artificial iris device (CustomFlex Artificial Iris; HumanOptics AG) for the treatment of congenital and acquired iris defects. DESIGN: Multicenter, prospective, unmasked, nonrandomized, interventional clinical trial. PARTICIPANTS: Patients with photophobia, sensitivity secondary to partial or complete congenital or acquired iris defects, or both. METHODS: Eyes were implanted from November 26, 2013, to December 1, 2017, with a custom, foldable artificial iris by 1 of 4 different surgical techniques. Patients were evaluated 1 day, 1 week, and 1, 3, 6, and 12 months after surgery. At each examination, slit-lamp findings, intraocular pressure, implant position, subjective visual symptoms, and complications were recorded. Corrected distance visual acuity (CDVA) and endothelial cell density (ECD) were measured at 3, 6, or 12 months as additional safety evaluations. The 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) was used to assess health-related quality of life affected by vision. The Global Aesthetic Improvement Scale was used to assess cosmetic results. MAIN OUTCOME MEASURES: Photosensitivity, glare, visual symptoms, NEI VFQ-25 score, Global Aesthetic Improvement Scale rating, prosthesis-related adverse events, intraocular lens (IOL)-related adverse events, and surgery-related adverse events 12 months after surgery. RESULTS: At the 12-month postoperative examination, a 59.7% reduction in marked to severe daytime light sensitivity (P < 0.0001), a 41.5% reduction in marked to severe nighttime light sensitivity (P < 0.0001), a 53.1% reduction in marked to severe daytime glare (P < 0.0001), and a 48.5% reduction in severe nighttime glare (P < 0.0001) were found. A 15.4-point improvement (P < 0.0001) in the NEI VFQ-25 total score was found, and 93.8% of patients reported an improvement in cosmesis as measured by the Global Aesthetic Improvement Scale 12 months after surgery. No loss of CDVA of > 2 lines related to the device was found. Median ECD loss was 5.3% at 6 months after surgery and 7.2% at 12 months after surgery. CONCLUSIONS: The artificial iris surpassed all key safety end points for adverse events related to the device, IOL, or implant surgery and met all key efficacy end points, including decreased light and glare sensitivity, improved health-related quality of life, and satisfaction with cosmesis. The device is safe and effective for the treatment of symptoms and an unacceptable cosmetic appearance created by congenital or acquired iris defects.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Ayres BD, Fant BS, Landis ZC, et al. Results of the United States Food and Drug Administration Clinical Trial of the CustomFlex Artificial Iris. Ophthalmology. 2022. PMID: 35131359. doi:10.1016/j.ophtha.2022.01.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。